Aa Mrc, Llc

Summary

Aa Mrc, Llc is a medical facility located in Flint, Michigan. This center is recognized for care of Type 2 Diabetes, Cardiovascular Disease, Gastroparesis, Atherosclerosis, Hypertriglyceridemia and other specialties. Aa Mrc, Llc is involved with conducting 32 clinical trials across 51 conditions. There are 1 research doctors associated with this hospital, such as Ahmed Arif.

Top PIs

Clinical Trials running at Aa Mrc, Llc

Cardiovascular Disease

Chronic Kidney Disease

Atherosclerosis

Type 2 Diabetes

Hypertension

Chronic Obstructive Pulmonary Disease

High Blood Pressure

Asthma

Diabetes

Von Willebrand Disease

Pelacarsen

for Cardiovascular Disease

This non-randomized, rollover extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed either of the double-blind parent studies (CTQJ230A12303 or CTQJ230A12304).

Recruiting

2 awards

Phase 3

Vicadrostat + Empagliflozin

for Type 2 Diabetes and Hypertension

This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empagliflozin, helps reduce cardiovascular risk in people with these conditions. The study will compare this combination to a placebo version of vicadrostat with empagliflozin. Participants are put into 2 groups randomly, which means by chance. One group takes vicadrostat and empagliflozin tablets, and the other group takes placebo tablets with empagliflozin. Placebo tablets look like vicadrostat tablets but do not contain any medicine. Participants take a tablet once per day for 2 and a half years and up to 4 years and 3 months. All participants also continue their medication for type 2 diabetes, high blood pressure, and cardiovascular disease. Participants have an equal chance of receiving the study medicine or placebo. Participants are in the study for up to 4 years and 3 months. During this time, they visit the study site regularly. During these visits, doctors collect information about participants' health and take blood samples. The doctors document when participants experience cardiovascular events. The doctors also regularly check participants' health and take note of any unwanted effects.

Recruiting

1 award

Phase 3

4 criteria

Pelacarsen

for Cardiovascular Disease

The purpose of the study CTQJ230A12304, is to evaluate the efficacy, safety, and tolerability of pelacarsen (TQJ230) compared to placebo in participants with ASCVD who have elevated lipoprotein(a) (Lp(a)), and who are on background inclisiran treatment for elevated low-density lipoprotein cholesterol (LDL-C).

Recruiting

1 award

Phase 3

3 criteria